Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis

By sjmartinez • May 1, 2024

Gu Y, Gebremariam T, Alkhazraji S, Youssef E, El-Gamal S, Matkovits T, Cobb J, Mannino R, Ibrahim AS. Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis. Antimicrob Agents Chemother. 2024 Apr 30:e0154023. doi: 10.1128/aac.01540-23. Epub ahead of print. PMID: 38687015.

Tags: Amphotericin B, antifungal agents, Harbor UCLA, Infectious Diseases, lipid nanocrystal, liposomal amphotericin B, MAT2203, mucor, mucormycosis, murine, oral amphotericin B, Publications, Rhizopus

ACTIV trials: cross-trial lessons learned for master protocol implementation

Keshtkar-Jahromi M, Adam SJ, Brar I, Chung LK, Currier JS, Daar ES, Davey VJ, Denning ET, Gelijns AC, Higgs ES, Jagannathan P, Javan AC, Jensen[...]

Hypokalemic periodic paralysis presenting as cardiac arrest

Joshi M, Salameh W, Vintch J, Goodman EL. Hypokalemic periodic paralysis presenting as cardiac arrest. BMJ Case Rep. 2024 Nov 13;17(11):e259889. doi: 10.1136/bcr-2024-259889. PMID: 39537393.

Aquaporin-4 Immunoglobulin G-seropositive Neuromyelitis Optica Spectrum Disorder MRI Characteristics: Data Analysis from the International Real-World PAMRINO Study Cohort

Chien C, Cruz E Silva V, Geiter E, Meier D, Zimmermann H, Bichuetti DB, Idagawa MI, Altintas A, Tanriverdi U, Siritho S, Pandit L, Dcunha[...]